Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Laura Hermann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Floxacillin, Anti-Bacterial Agents, Staphylococcal Infections, Bacteremia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Optimal antibiotic dosing for Staphylococcus aureus bloodstream infections (BSI) is still controversial. One reason is inter-individual variation in pharmacokinetics, which may be influenced by various patient-related factors, particularly in critically ill patients.
Objectives
To describe the population pharmacokinetics (PopPK) of the antibiotic flucloxacillin in patients with S. aureus BSI. Subsequently, we sought to translate the model into a user-friendly app for generating a priori and a posteriori time–concentration curves and dose recommendations to optimize dosing regimens.
Methods
Total and unbound flucloxacillin concentrations were included from 49 patients from a prospective cohort study conducted during clinical routine, including non-critically ill and critically ill individuals who received intermittent bolus applications. These data were analysed using non-linear mixed-effects modelling.
Results
Most patients (98%) were treated with 2 g of flucloxacillin every 4 h. We developed a joint model that simultaneously described total and unbound concentrations. The model included an allometric effect of glomerular filtration rate on clearance and albumin on the albumin dissociation constant. The latter was especially important, as in our population the unbound fraction was higher at 11.5% (16.7% for critically ill patients) compared with reported values of approximately 5%. Based on our joint model, we developed a web-based app for optimizing dosing regimens of flucloxacillin.
Conclusions
By utilizing data from clinical routine, we were able to create a predictive PopPK model of flucloxacillin and identify influential covariates. The web-based app is currently being validated in a clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Bern, Bern, Switzerland.
- Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.
- Department of Clinical Research, University of Basel, Basel, Switzerland.
- Division of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
- Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
ORCID-Profile: Verena Schöning, Katharina Rentsch, Michael Osthoff, Felix Hammann
Zitieren
APA
Hermann, L., Schöning, V., Dräger, S., Rentsch, K., Moser, S., Gürtler, N., Sendi, P., Osthoff, M., & Hammann, F. (2024). Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae207
Vancouver
Hermann L, Schöning V, Dräger S, Rentsch K, Moser S, Gürtler N, et al. Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae207
BibTeX
@article{Hermann2024,
author = {Hermann, Laura and Schöning, Verena and Dräger, Sarah and Rentsch, Katharina and Moser, Stephan and Gürtler, Nicolas and Sendi, Parham and Osthoff, Michael and Hammann, Felix},
title = {Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae207}
}
EUVIMED